Mesoblast to aquire further stem cell assets – Sydney Morning Herald
|
Mesoblast to aquire further stem cell assets
Sydney Morning Herald Stem cell group Mesoblast is to outlay up to $US100 million on a US acquisition as it ramps up its product development pipeline and broadens its suite of patents. It is to acquire the stem cell assets of Osiris Therapeutic for an initial $US20 million … Osiris Announces Agreement for Culture-Expanded MSCs Including Prochymal …Wall Street Journal |
